首页 > 最新文献

Current drug safety最新文献

英文 中文
Development of Dermatomyositis after Pfizer BioNTeh COVID-19 Vaccine: A Case Report. 辉瑞 BioNTeh COVID-19 疫苗引发皮肌炎:病例报告。
IF 1.5 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230614164607
Imen Aouintia, Wiem Daly, Ghozlane Lakhoua, Widd Kaabi, Ons Charfi, Sana Debbeche, Sarrah Kastalli, Ahmed Zaiem, Sihem El Aidli

Introduction: The Coronavirus Disease 2019 (COVID-19) pandemic led to the fast development of vaccines, which is considered a medical advance in healthcare. With the extensive vaccination campaign performed worldwide, many adverse events following immunization (AEFI) were reported. Most of them were flu-like symptoms, mild and self-limiting. However, serious adverse events, such as dermatomyositis (DM), an idiopathic autoimmune connective tissue disease, have also been reported.

Case presentation: In this report, we describe a case of skin erythema, edema, and diffuse myalgia attributed at first to Pfizer BioNTeh, COVID-19 vaccination, given the temporal relationship and the absence of significant medical history. The causality assessment score was I1B2. However, after completing the etiological assessment, an invasive breast carcinoma was identified, and we retained the diagnosis of paraneoplastic DM.

Conclusion: This study underlines the importance of completing the etiological assessment before attributing any adverse reaction to vaccination to maintain optimal patient care.

导言:2019 年冠状病毒病(COVID-19)大流行促使疫苗迅速发展,这被认为是医疗保健领域的一大进步。随着全球范围内广泛开展疫苗接种活动,许多免疫接种后不良事件(AEFI)被报道出来。其中大多数是类似流感的症状,症状轻微且有自限性。但也有严重不良事件的报道,如皮肌炎(DM),这是一种特发性自身免疫性结缔组织疾病:在本报告中,我们描述了一例皮肤红斑、水肿和弥漫性肌痛病例,考虑到时间关系和无重要病史,起初将其归因于辉瑞 BioNTeh COVID-19 疫苗接种。因果关系评估得分为 I1B2。然而,在完成病因评估后,发现了浸润性乳腺癌,我们保留了副肿瘤性 DM 的诊断:本研究强调了在将任何不良反应归因于疫苗接种之前完成病因学评估的重要性,以保持对患者的最佳护理。
{"title":"Development of Dermatomyositis after Pfizer BioNTeh COVID-19 Vaccine: A Case Report.","authors":"Imen Aouintia, Wiem Daly, Ghozlane Lakhoua, Widd Kaabi, Ons Charfi, Sana Debbeche, Sarrah Kastalli, Ahmed Zaiem, Sihem El Aidli","doi":"10.2174/1574886318666230614164607","DOIUrl":"10.2174/1574886318666230614164607","url":null,"abstract":"<p><strong>Introduction: </strong>The Coronavirus Disease 2019 (COVID-19) pandemic led to the fast development of vaccines, which is considered a medical advance in healthcare. With the extensive vaccination campaign performed worldwide, many adverse events following immunization (AEFI) were reported. Most of them were flu-like symptoms, mild and self-limiting. However, serious adverse events, such as dermatomyositis (DM), an idiopathic autoimmune connective tissue disease, have also been reported.</p><p><strong>Case presentation: </strong>In this report, we describe a case of skin erythema, edema, and diffuse myalgia attributed at first to Pfizer BioNTeh, COVID-19 vaccination, given the temporal relationship and the absence of significant medical history. The causality assessment score was I1B2. However, after completing the etiological assessment, an invasive breast carcinoma was identified, and we retained the diagnosis of paraneoplastic DM.</p><p><strong>Conclusion: </strong>This study underlines the importance of completing the etiological assessment before attributing any adverse reaction to vaccination to maintain optimal patient care.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"306-308"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9633642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Remimazolam and Remifentanil Use Induced Severe Respiratory Depression and Laryngeal Spasm During Intravenous Sedation and Analgesia: A Case Report. 静脉镇静镇痛时使用雷马唑仑和瑞芬太尼引起严重呼吸抑制和喉痉挛1例。
IF 1.5 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230517101142
Zhijun Xin, Ning Wang, Huaizhou Wang

Introduction: Intravenous sedation and analgesia are widely used in minor surgeries. Remifentanil and remimazolam are advantageous in this setting because of their rapid onset of action, and short duration of action leading to a rapid recovery. However, the two drugs combined need to be titrated to avoid airway-related adverse events.

Case presentation: This article reports a case of severe respiratory depression and severe laryngeal spasm induced by remifentanil and remimazolam when they were used for analgesia and sedation in a patient undergoing oral biopsy.

Conclusion: We aim to improve awareness about the safety of these drugs among anesthesiologists and increase their ability to manage the risk associated with their use.

静脉镇静镇痛在小手术中应用广泛。瑞芬太尼和雷马唑仑在这种情况下是有利的,因为它们起效快,作用时间短,恢复迅速。然而,这两种药物联合需要滴定,以避免气道相关的不良事件。病例介绍:这篇文章报告了一例严重的呼吸抑制和严重的喉部痉挛,当病人接受口腔活检时,瑞芬太尼和雷马唑仑被用于镇痛和镇静。结论:本研究旨在提高麻醉医师对该类药物安全性的认识,提高麻醉医师管理该类药物使用风险的能力。
{"title":"Remimazolam and Remifentanil Use Induced Severe Respiratory Depression and Laryngeal Spasm During Intravenous Sedation and Analgesia: A Case Report.","authors":"Zhijun Xin, Ning Wang, Huaizhou Wang","doi":"10.2174/1574886318666230517101142","DOIUrl":"10.2174/1574886318666230517101142","url":null,"abstract":"<p><strong>Introduction: </strong>Intravenous sedation and analgesia are widely used in minor surgeries. Remifentanil and remimazolam are advantageous in this setting because of their rapid onset of action, and short duration of action leading to a rapid recovery. However, the two drugs combined need to be titrated to avoid airway-related adverse events.</p><p><strong>Case presentation: </strong>This article reports a case of severe respiratory depression and severe laryngeal spasm induced by remifentanil and remimazolam when they were used for analgesia and sedation in a patient undergoing oral biopsy.</p><p><strong>Conclusion: </strong>We aim to improve awareness about the safety of these drugs among anesthesiologists and increase their ability to manage the risk associated with their use.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"277-281"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9851335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Gambia Death Story: 66 Children Died! 冈比亚的死亡故事:66 名儿童死亡!
IF 1.5 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230726161911
Sumel Ashique
{"title":"The Gambia Death Story: 66 Children Died!","authors":"Sumel Ashique","doi":"10.2174/1574886318666230726161911","DOIUrl":"10.2174/1574886318666230726161911","url":null,"abstract":"","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"160-162"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9867502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment Modalities for Trigeminal Neuralgia and the Need for Vigilance in Monitoring Adverse Drug Events: A Case Report. 三叉神经痛的治疗模式与监测药物不良事件的必要性:病例报告。
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/0115748863215954231214073053
Raja Narendra Divakar Addanki, Anjali Srikanth Mannava, Hemasri Velmurugan, Pugazhenthan Thangaraju

Introduction: Trigeminal neuralgia is a rare condition characterised by paroxysms of intense pain in the distribution of the trigeminal nerve. This condition significantly diminishes the patient's quality of life, and the side effects from chronic use of medications for symptomatic relief further exacerbate their distress.

Case description: The case report discusses a patient diagnosed with Trigeminal Neuralgia who commenced carbamazepine treatment. The report tracks the disease's progression, medication adjustments, and the eventual emergence of vertigo due to long-term carbamazepine use.

Conclusion: The article covers fundamental information about trigeminal neuralgia and its management and also offers a comprehensive review of the basics of vertigo. It delves into carbamazepine's mechanism of action and its associated side effects. The paper also looks at prospective therapy changes that could improve patients' quality of life.

简介三叉神经痛是一种罕见的疾病,其特征是三叉神经分布区阵发性剧烈疼痛。这种疾病大大降低了患者的生活质量,而长期使用药物缓解症状所产生的副作用进一步加剧了患者的痛苦:本病例报告讨论了一名被诊断为三叉神经痛的患者,该患者开始接受卡马西平治疗。报告追踪了该疾病的进展、药物调整以及因长期服用卡马西平而最终出现的眩晕:文章涵盖了三叉神经痛及其治疗的基本信息,还全面回顾了眩晕的基本知识。文章深入探讨了卡马西平的作用机制及其相关副作用。文章还探讨了可改善患者生活质量的前瞻性疗法改变。
{"title":"Treatment Modalities for Trigeminal Neuralgia and the Need for Vigilance in Monitoring Adverse Drug Events: A Case Report.","authors":"Raja Narendra Divakar Addanki, Anjali Srikanth Mannava, Hemasri Velmurugan, Pugazhenthan Thangaraju","doi":"10.2174/0115748863215954231214073053","DOIUrl":"10.2174/0115748863215954231214073053","url":null,"abstract":"<p><strong>Introduction: </strong>Trigeminal neuralgia is a rare condition characterised by paroxysms of intense pain in the distribution of the trigeminal nerve. This condition significantly diminishes the patient's quality of life, and the side effects from chronic use of medications for symptomatic relief further exacerbate their distress.</p><p><strong>Case description: </strong>The case report discusses a patient diagnosed with Trigeminal Neuralgia who commenced carbamazepine treatment. The report tracks the disease's progression, medication adjustments, and the eventual emergence of vertigo due to long-term carbamazepine use.</p><p><strong>Conclusion: </strong>The article covers fundamental information about trigeminal neuralgia and its management and also offers a comprehensive review of the basics of vertigo. It delves into carbamazepine's mechanism of action and its associated side effects. The paper also looks at prospective therapy changes that could improve patients' quality of life.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"482-488"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139416595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multiple Sclerosis Risk Among Anti-tumor Necrosis Factor Alpha Users: A Methodological Review of Observational Studies Based on Real-world Data. 抗肿瘤坏死因子α使用者患多发性硬化症的风险:基于真实世界数据的观察性研究的方法学回顾。
IF 1.5 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230726162245
Lingyi Li, Mahyar Etminan, Gilaad G Kaplan, Helen Tremlett, Hui Xie, J Antonio Aviña-Zubieta

Epidemiologic studies on the risk of multiple sclerosis (MS) or demyelinating events associated with anti-tumor necrosis factor alpha (TNFα) use among patients with rheumatic diseases or inflammatory bowel diseases have shown conflicting results. Causal directed acyclic graphs (cDAGs) are useful tools for understanding the differing results and identifying the structure of potential contributing biases. Most of the available literature on cDAGs uses language that might be unfamiliar to clinicians. This article demonstrates how cDAGs can be used to determine whether there is a confounder, a mediator or collider-stratification bias and when to adjust for them appropriately. We also use a case study to show how to control for potential biases by drawing a cDAG depicting anti-TNFα use and its potential to contribute to MS onset. Finally, we describe potential biases that might have led to contradictory results in previous studies that examined the effect of anti-TNFα and MS, including confounding, confounding by contraindication, and bias due to measurement error. Clinicians and researchers should be cognizant of confounding, confounding by contraindication, and bias due to measurement error when reviewing future studies on the risk of MS or demyelinating events associated with anti-TNFα use. cDAGs are a useful tool for selecting variables and identifying the structure of different biases that can affect the validity of observational studies.

关于风湿病或炎症性肠病患者使用抗肿瘤坏死因子α(TNFα)导致多发性硬化症(MS)或脱髓鞘事件风险的流行病学研究显示了相互矛盾的结果。因果有向无环图(cDAG)是了解不同结果和识别潜在偏差结构的有用工具。关于 cDAGs 的现有文献大多使用临床医生可能不熟悉的语言。本文展示了如何使用 cDAGs 来确定是否存在混杂因素、中介因素或对撞分层偏倚,以及何时对其进行适当调整。我们还通过一个案例研究,展示了如何通过绘制 cDAG 来控制潜在的偏倚,cDAG 描述了抗肿瘤坏死因子α的使用及其对多发性硬化症发病的潜在影响。最后,我们描述了以往研究抗肿瘤坏死因子α与多发性硬化症影响时可能导致矛盾结果的潜在偏倚,包括混杂因素、禁忌症混杂因素以及测量误差导致的偏倚。临床医生和研究人员在审查未来与使用抗肿瘤坏死因子α相关的多发性硬化症或脱髓鞘事件风险研究时,应认识到混杂因素、禁忌症混杂因素和测量误差导致的偏倚。cDAG 是一种有用的工具,可用于选择变量和识别可能影响观察性研究有效性的不同偏倚的结构。
{"title":"Multiple Sclerosis Risk Among Anti-tumor Necrosis Factor Alpha Users: A Methodological Review of Observational Studies Based on Real-world Data.","authors":"Lingyi Li, Mahyar Etminan, Gilaad G Kaplan, Helen Tremlett, Hui Xie, J Antonio Aviña-Zubieta","doi":"10.2174/1574886318666230726162245","DOIUrl":"10.2174/1574886318666230726162245","url":null,"abstract":"<p><p>Epidemiologic studies on the risk of multiple sclerosis (MS) or demyelinating events associated with anti-tumor necrosis factor alpha (TNFα) use among patients with rheumatic diseases or inflammatory bowel diseases have shown conflicting results. Causal directed acyclic graphs (cDAGs) are useful tools for understanding the differing results and identifying the structure of potential contributing biases. Most of the available literature on cDAGs uses language that might be unfamiliar to clinicians. This article demonstrates how cDAGs can be used to determine whether there is a confounder, a mediator or collider-stratification bias and when to adjust for them appropriately. We also use a case study to show how to control for potential biases by drawing a cDAG depicting anti-TNFα use and its potential to contribute to MS onset. Finally, we describe potential biases that might have led to contradictory results in previous studies that examined the effect of anti-TNFα and MS, including confounding, confounding by contraindication, and bias due to measurement error. Clinicians and researchers should be cognizant of confounding, confounding by contraindication, and bias due to measurement error when reviewing future studies on the risk of MS or demyelinating events associated with anti-TNFα use. cDAGs are a useful tool for selecting variables and identifying the structure of different biases that can affect the validity of observational studies.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"200-207"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9877078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Amphotericin-B-Induced Chronic Kidney Disease in a Post-COVID-19 Patient with Widespread Rhinocerebral Mucormycosis and Pneumonia: A Case Report. 一个病例报告:COVID-19 后患者的两性霉素-B 诱导的慢性肾病,患者患有广泛的犀脑粘液瘤病和肺炎:病例报告。
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230804101539
Nishant Johri, Ambika Choudhary, Ujjawal Rawat, Maheshwari Vengat

Background: The COVID-19 pandemic has posed a unique challenge to the medical community due to potential co-infections with bacteria and fungi. We report a case of Rhino cerebral mucormycosis infection in a 67-year-old patient after recovery from COVID-19.

Objective: To report a case of Rhino cerebral mucormycosis in a 67-year-old patient with preexisting health conditions after recovering from COVID-19 and to highlight the importance of early detection and treatment of co-infections in patients with pre-existing health conditions.

Case presentation: The patient had pre-existing health conditions, including uncontrolled diabetes, hypertension, and Chronic obstructive pulmonary disease (COPD), which made him more vulnerable to complications after COVID-19. He was admitted to the hospital after experiencing a dark discharge from his left eye, later confirmed to be due to mucormycosis. Histopathological examination revealed invasive mucormycosis, highlighting the importance of early detection and treatment. However, the patient experienced Acute kidney injury (AKI) after only 5 days of treatment with conventional amphotericin B, underscoring the need for careful monitoring and adjustment of treatment regimens.

Discussion: The case underscores the need for early detection and treatment of co-infections in vulnerable patients. The patient's pre-existing conditions and immunocompromised state made him more susceptible to the infection. The case also highlights the importance of careful monitoring and adjustment of treatment regimens to minimize the risk of adverse effects.

Conclusion: While COVID-19 has presented challenges and uncertainties, it has also provided valuable insights into the interactions between infectious agents and the human body. Continued research and vigilance are necessary to mitigate the impact of co-infections and improve outcomes for patients.

背景:COVID-19 大流行给医学界带来了独特的挑战,因为它可能与细菌和真菌同时感染。我们报告了一例从 COVID-19 中康复后感染犀牛脑粘孢子菌病的 67 岁患者:报告一例从 COVID-19 康复后感染犀牛脑粘液瘤病的 67 岁患者的病例,并强调早期发现和治疗合并感染对已有健康状况的患者的重要性:病例介绍:该患者原有健康状况,包括糖尿病、高血压和慢性阻塞性肺病(COPD)未得到控制,这使他在感染 COVID-19 后更容易出现并发症。他因左眼出现黑眼屎而入院,后证实为粘液瘤病所致。组织病理学检查显示为浸润性粘孢子菌病,这凸显了早期发现和治疗的重要性。然而,患者在接受常规两性霉素 B 治疗仅 5 天后就出现了急性肾损伤(AKI),这凸显了仔细监测和调整治疗方案的必要性:讨论:该病例强调了对易感患者合并感染进行早期检测和治疗的必要性。患者原有的疾病和免疫力低下的状态使其更容易受到感染。该病例还强调了仔细监测和调整治疗方案以尽量减少不良反应风险的重要性:尽管 COVID-19 带来了挑战和不确定性,但它也为我们了解传染病病原体与人体之间的相互作用提供了宝贵的启示。要减轻合并感染的影响并改善患者的治疗效果,就必须继续开展研究并保持警惕。
{"title":"Amphotericin-B-Induced Chronic Kidney Disease in a Post-COVID-19 Patient with Widespread Rhinocerebral Mucormycosis and Pneumonia: A Case Report.","authors":"Nishant Johri, Ambika Choudhary, Ujjawal Rawat, Maheshwari Vengat","doi":"10.2174/1574886318666230804101539","DOIUrl":"10.2174/1574886318666230804101539","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic has posed a unique challenge to the medical community due to potential co-infections with bacteria and fungi. We report a case of Rhino cerebral mucormycosis infection in a 67-year-old patient after recovery from COVID-19.</p><p><strong>Objective: </strong>To report a case of Rhino cerebral mucormycosis in a 67-year-old patient with preexisting health conditions after recovering from COVID-19 and to highlight the importance of early detection and treatment of co-infections in patients with pre-existing health conditions.</p><p><strong>Case presentation: </strong>The patient had pre-existing health conditions, including uncontrolled diabetes, hypertension, and Chronic obstructive pulmonary disease (COPD), which made him more vulnerable to complications after COVID-19. He was admitted to the hospital after experiencing a dark discharge from his left eye, later confirmed to be due to mucormycosis. Histopathological examination revealed invasive mucormycosis, highlighting the importance of early detection and treatment. However, the patient experienced Acute kidney injury (AKI) after only 5 days of treatment with conventional amphotericin B, underscoring the need for careful monitoring and adjustment of treatment regimens.</p><p><strong>Discussion: </strong>The case underscores the need for early detection and treatment of co-infections in vulnerable patients. The patient's pre-existing conditions and immunocompromised state made him more susceptible to the infection. The case also highlights the importance of careful monitoring and adjustment of treatment regimens to minimize the risk of adverse effects.</p><p><strong>Conclusion: </strong>While COVID-19 has presented challenges and uncertainties, it has also provided valuable insights into the interactions between infectious agents and the human body. Continued research and vigilance are necessary to mitigate the impact of co-infections and improve outcomes for patients.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"474-477"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9988645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence and Severity of Adverse Drug Reactions in Medical Intensive Care Unit. 内科重症监护室药物不良反应的发生率和严重程度。
IF 1.1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230816090606
Sana Shaikh, Asawari Raut, Prajkta Jambhale, Shivkumar Iyer, Jignesh Shah

Background: Adverse drug reactions (ADRs) curtail patients' quality of life by virtue of increasing therapeutic complexity and rising multimorbidity. In India, the frequency of ADRs for individual drugs and their economic burdens are rarely evaluated. This study aimed at identifying the incidence and severity of ADRs leading to hospitalization (ADRA) and occurring during a hospital stay (ADRH).

Objective: The objective of this study is to evaluate the incidence the incidence and severity of ADRs in the ICU and their impact on the duration of hospitalization, along with the cost incurred to treat ADRs in the ICU.

Methods: Demographic, clinical, and pharmacological data on patients admitted to the ICU were collected, analyzed and evaluated for ADRs. According to the setting analyzed, a descriptive analysis of the reactions, suspected medicines, and associated factors was undertaken.

Results: A total of 208 patients were admitted to the ICU during the study period, of which ADRA contributed 9.1% of the incidence rate and 8.1% of ADRH in 36 patients. Males had a higher incidence of ADRs than females. Patients who had ADRs had a substantially longer length of stay than those who did not. Electrolyte disturbance was the most commonly found ADR. According to the Hartwig scale and WHO-causality scale, 88.9% were moderate, and 97.2% were possible ADRs, respectively.

Conclusion: In this study, a similar incidence rate of ADRA and ADRH was observed. The average cost for treating ADRA was higher than that for treating ADRH. As a result, identifying and preventing these reactions is critical, as they cause the patient greater suffering.

背景:药物不良反应(ADRs)因治疗的复杂性和多病症的增加而降低了患者的生活质量。在印度,对个别药物的不良反应频率及其经济负担很少进行评估。本研究旨在确定导致住院(ADRA)和住院期间发生(ADRH)的 ADR 的发生率和严重程度:本研究旨在评估重症监护室 ADR 的发生率和严重程度及其对住院时间的影响,以及治疗重症监护室 ADR 所产生的费用:方法:收集、分析和评估重症监护室住院患者的人口统计学、临床和药理学数据。根据分析的环境,对反应、可疑药物和相关因素进行了描述性分析:研究期间,重症监护室共收治了 208 名患者,其中 36 名患者的 ADRA 发生率为 9.1%,ADRH 发生率为 8.1%。男性的 ADR 发生率高于女性。出现 ADR 的患者的住院时间远远长于未出现 ADR 的患者。电解质紊乱是最常见的 ADR。根据哈特维格量表和世界卫生组织因果关系量表,88.9%为中度不良反应,97.2%为可能的不良反应:本研究观察到 ADRA 和 ADRH 的发生率相似。治疗 ADRA 的平均费用高于治疗 ADRH 的平均费用。因此,识别和预防这些反应至关重要,因为它们会给患者带来更大的痛苦。
{"title":"Incidence and Severity of Adverse Drug Reactions in Medical Intensive Care Unit.","authors":"Sana Shaikh, Asawari Raut, Prajkta Jambhale, Shivkumar Iyer, Jignesh Shah","doi":"10.2174/1574886318666230816090606","DOIUrl":"10.2174/1574886318666230816090606","url":null,"abstract":"<p><strong>Background: </strong>Adverse drug reactions (ADRs) curtail patients' quality of life by virtue of increasing therapeutic complexity and rising multimorbidity. In India, the frequency of ADRs for individual drugs and their economic burdens are rarely evaluated. This study aimed at identifying the incidence and severity of ADRs leading to hospitalization (ADRA) and occurring during a hospital stay (ADRH).</p><p><strong>Objective: </strong>The objective of this study is to evaluate the incidence the incidence and severity of ADRs in the ICU and their impact on the duration of hospitalization, along with the cost incurred to treat ADRs in the ICU.</p><p><strong>Methods: </strong>Demographic, clinical, and pharmacological data on patients admitted to the ICU were collected, analyzed and evaluated for ADRs. According to the setting analyzed, a descriptive analysis of the reactions, suspected medicines, and associated factors was undertaken.</p><p><strong>Results: </strong>A total of 208 patients were admitted to the ICU during the study period, of which ADRA contributed 9.1% of the incidence rate and 8.1% of ADRH in 36 patients. Males had a higher incidence of ADRs than females. Patients who had ADRs had a substantially longer length of stay than those who did not. Electrolyte disturbance was the most commonly found ADR. According to the Hartwig scale and WHO-causality scale, 88.9% were moderate, and 97.2% were possible ADRs, respectively.</p><p><strong>Conclusion: </strong>In this study, a similar incidence rate of ADRA and ADRH was observed. The average cost for treating ADRA was higher than that for treating ADRH. As a result, identifying and preventing these reactions is critical, as they cause the patient greater suffering.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"332-341"},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10014614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polymeric Micelles as Drug Delivery System: Recent Advances, Approaches, Applications and Patents. 作为给药系统的聚合物胶束:最新进展、方法、应用和专利。
IF 1.5 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230605120433
Anushka Jain, Kamini Bhardwaj, Mukesh Bansal

Administering therapeutics through the oral route is a pervasive and widely approved medication administration approach. However, it has been found that many drugs show low systemic absorption when delivered through this route. Such limitations of oral drug delivery can be overcome by polymeric micelles acting as vehicles. As a result, they improve drug absorption by protecting loaded drug substances from the gastrointestinal system's hostile conditions, allowing controlled drug release at a specific site, extending the time spent in the gut through mucoadhesion, and inhibiting the efflux pump from reducing therapeutic agent accumulation. To promote good oral absorption of a weakly water-soluble medicinal drug, the loaded medicine should be protected from the hostile atmosphere of the GI tract. Polymeric micelles can be stacked with a broad assortment of ineffectively dissolvable medications, improving bioavailability. This review discusses the major mechanism, various types, advantages, and limitations for developing the polymeric micelle system and certain micellar drug delivery system applications. The primary goal of this review is to illustrate how polymeric micelles can be used to deliver poorly water-soluble medications.

通过口服途径给药是一种普遍且被广泛认可的给药方法。然而,人们发现,许多药物在通过这一途径给药时,全身吸收率较低。作为载体的聚合物胶束可以克服口服给药的这些局限性。因此,它们可以通过保护负载的药物物质免受胃肠道系统恶劣环境的影响、在特定部位控制药物释放、通过粘液粘附延长在肠道中的停留时间以及抑制外排泵减少治疗药物的积累,从而改善药物吸收。要促进弱水溶性药物的良好口服吸收,就必须保护所含药物不受消化道不良环境的影响。聚合胶束可与各种无效溶解药物叠加,从而提高生物利用度。本综述讨论了开发聚合物胶束系统和某些胶束给药系统应用的主要机制、各种类型、优势和局限性。本综述的主要目的是说明聚合物胶束如何用于递送水溶性差的药物。
{"title":"Polymeric Micelles as Drug Delivery System: Recent Advances, Approaches, Applications and Patents.","authors":"Anushka Jain, Kamini Bhardwaj, Mukesh Bansal","doi":"10.2174/1574886318666230605120433","DOIUrl":"10.2174/1574886318666230605120433","url":null,"abstract":"<p><p>Administering therapeutics through the oral route is a pervasive and widely approved medication administration approach. However, it has been found that many drugs show low systemic absorption when delivered through this route. Such limitations of oral drug delivery can be overcome by polymeric micelles acting as vehicles. As a result, they improve drug absorption by protecting loaded drug substances from the gastrointestinal system's hostile conditions, allowing controlled drug release at a specific site, extending the time spent in the gut through mucoadhesion, and inhibiting the efflux pump from reducing therapeutic agent accumulation. To promote good oral absorption of a weakly water-soluble medicinal drug, the loaded medicine should be protected from the hostile atmosphere of the GI tract. Polymeric micelles can be stacked with a broad assortment of ineffectively dissolvable medications, improving bioavailability. This review discusses the major mechanism, various types, advantages, and limitations for developing the polymeric micelle system and certain micellar drug delivery system applications. The primary goal of this review is to illustrate how polymeric micelles can be used to deliver poorly water-soluble medications.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"163-171"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9764005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Amoxicillin Induced Fever, Rash, and Catatonia - A Case Study. 阿莫西林诱发发热、皮疹和紧张症--病例研究。
IF 1.5 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230308094209
Chunnu Kumar Yadav, Rajat Ranka, Prasan Kumar Panda, Bishal Pratap Shah, Mayank Kumar Mishra, Vijay Krishnan

Introduction: Adverse drug reactions (ADR) are defined as any harmful or unpleasant events or injuries resulting from the use of any particular drug. Among those antibiotics that cause adverse reactions, amoxicillin is one of them. Catatonia and vasculitic rash are its rare adverse effects.

Case presentation: A 23-year-old postpartum female, with a history of taking empirical Amoxiclav (amoxicillin-clavulanic acid 625 mg) injection and oral tablets for episiotomy wound, presented with altered sensorium and fever followed by maculopapular rash. On examination, she had generalized rigidity with waxy flexibility that improved by lorazepam challenge and was diagnosed as catatonia. On evaluation, amoxicillin was found to be precipitating catatonia in this patient.

Conclusion: Since the diagnosis of catatonia is often missed, any cases with clinical presentation of fever, rash, altered sensorium, and generalized rigidity should also be suspected for druginduced ADR and the precipitating factor should be searched for.

导言:药物不良反应(ADR)是指因使用任何特定药物而导致的任何有害或令人不快的事件或伤害。在引起不良反应的抗生素中,阿莫西林是其中之一。紧张症和血管性皮疹是其罕见的不良反应:一名 23 岁的产后女性,曾因外阴切开术伤口服用经验性 Amoxiclav(阿莫西林-克拉维酸 625 毫克)注射剂和口服片剂。经检查,她全身僵硬,有蜡样弹性,服用劳拉西泮后有所改善,被诊断为紧张性精神障碍。评估发现,阿莫西林会诱发该患者的紧张性精神障碍:结论:由于紧张症的诊断经常被漏诊,因此任何临床表现为发热、皮疹、感觉改变和全身僵硬的病例也应怀疑药物诱发的 ADR,并寻找诱发因素。
{"title":"Amoxicillin Induced Fever, Rash, and Catatonia - A Case Study.","authors":"Chunnu Kumar Yadav, Rajat Ranka, Prasan Kumar Panda, Bishal Pratap Shah, Mayank Kumar Mishra, Vijay Krishnan","doi":"10.2174/1574886318666230308094209","DOIUrl":"10.2174/1574886318666230308094209","url":null,"abstract":"<p><strong>Introduction: </strong>Adverse drug reactions (ADR) are defined as any harmful or unpleasant events or injuries resulting from the use of any particular drug. Among those antibiotics that cause adverse reactions, amoxicillin is one of them. Catatonia and vasculitic rash are its rare adverse effects.</p><p><strong>Case presentation: </strong>A 23-year-old postpartum female, with a history of taking empirical Amoxiclav (amoxicillin-clavulanic acid 625 mg) injection and oral tablets for episiotomy wound, presented with altered sensorium and fever followed by maculopapular rash. On examination, she had generalized rigidity with waxy flexibility that improved by lorazepam challenge and was diagnosed as catatonia. On evaluation, amoxicillin was found to be precipitating catatonia in this patient.</p><p><strong>Conclusion: </strong>Since the diagnosis of catatonia is often missed, any cases with clinical presentation of fever, rash, altered sensorium, and generalized rigidity should also be suspected for druginduced ADR and the precipitating factor should be searched for.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"282-285"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9077524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Methotrexate-induced Severe Pancytopenia in a Patient with Rheumatoid Arthritis: A Case Report and Review of Literature. 一名类风湿性关节炎患者甲氨蝶呤诱发的全血细胞严重减少:病例报告和文献综述。
IF 1.5 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230516115737
Elham Hosseini, Foroud Shahbazi

Toxicity associated with low doses of methotrexate (MTX) is low, but it may be fatal. Bone marrow suppression and mucositis are among the common side effects of low dose MTX toxicity. Different risk factors have been reported for toxicities associated with low doses of MTX, including accidental use of higher doses, renal dysfunction, hypoalbuminemia, and polypharmacy. In this paper, we present a female patient who had mistakenly used 7.5 mg of MTX daily instead of the same dose of MTX on Thursday and Friday. She was presented with mucositis and diarrhea to the emergency department. Moreover, we searched the databases Scopus and PubMed for available studies and case reports on toxicities associated with MTX dosing errors. The most frequently observed toxicities included gastrointestinal lesions, nausea, vomiting, skin lesions, and bone marrow suppression. Leucovorin, hydration, and urine alkalinization were among the most frequently used treatments. Finally, we summarize the data on the toxicities of low doses of MTX in different diseases.

小剂量甲氨蝶呤(MTX)的毒性较低,但可能致命。骨髓抑制和粘膜炎是小剂量MTX毒性的常见副作用。据报道,低剂量MTX中毒的风险因素各不相同,包括意外使用较大剂量、肾功能障碍、低白蛋白血症和多药并用。在本文中,我们介绍了一名女性患者,她在周四和周五误服了每天 7.5 毫克的 MTX,而不是相同剂量的 MTX。她在急诊科就诊时出现了粘膜炎和腹泻。此外,我们还在 Scopus 和 PubMed 数据库中搜索了与 MTX 剂量错误相关的毒性研究和病例报告。最常见的毒性包括胃肠道病变、恶心、呕吐、皮肤病变和骨髓抑制。亮菌甲素、补液和尿碱化是最常用的治疗方法。最后,我们总结了小剂量 MTX 在不同疾病中的毒性数据。
{"title":"Methotrexate-induced Severe Pancytopenia in a Patient with Rheumatoid Arthritis: A Case Report and Review of Literature.","authors":"Elham Hosseini, Foroud Shahbazi","doi":"10.2174/1574886318666230516115737","DOIUrl":"10.2174/1574886318666230516115737","url":null,"abstract":"<p><p>Toxicity associated with low doses of methotrexate (MTX) is low, but it may be fatal. Bone marrow suppression and mucositis are among the common side effects of low dose MTX toxicity. Different risk factors have been reported for toxicities associated with low doses of MTX, including accidental use of higher doses, renal dysfunction, hypoalbuminemia, and polypharmacy. In this paper, we present a female patient who had mistakenly used 7.5 mg of MTX daily instead of the same dose of MTX on Thursday and Friday. She was presented with mucositis and diarrhea to the emergency department. Moreover, we searched the databases Scopus and PubMed for available studies and case reports on toxicities associated with MTX dosing errors. The most frequently observed toxicities included gastrointestinal lesions, nausea, vomiting, skin lesions, and bone marrow suppression. Leucovorin, hydration, and urine alkalinization were among the most frequently used treatments. Finally, we summarize the data on the toxicities of low doses of MTX in different diseases.</p>","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":"224-235"},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9469702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Current drug safety
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1